ArticleDiscover oncology2025
Identification of FGF14-AS2/MPP2 axis as prognostic biomarkers in colorectal cancer based on CeRNA network.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundColorectal cancer (CRC) remains a major global health challenge due to its high morbidity and mortality, even with recent advancements in diagnosis and treatment. Increasing evidence suggests that competitive endogenous RNA (ceRNA) regulatory networks play pivotal roles in the pathogenesis of various cancers, including CRC. However, the potential application of ceRNA networks in CRC diagnosis and their underlying mechanisms remain insufficiently explored.
methodsThe gene expression profiles and clinical information of CRC were extracted from TCGA database and GEO databases. Differential expression genes (DEGs) were identified using bioinformatics analyses, a ceRNA network was constructed via Cytoscape. Functional enrichment was assessed through GO and KEGG analyses, while hub genes were identified using the STRING database and cytoHubba plugin. Key prognostic genes were determined through univariate/multivariate Cox analysis, Kaplan-Meier analysis and correlation analysis. The expression of prognostically relevant lncRNAs and mRNAs was validated by qRT-PCR and GEO database A prognostic model was developed using univariate/multivariate COX analysis and Lasso regression analysis, and its performance was assessed via ROC and Kaplan-Meier analysis in TCGA and GSE39582 database. Drug sensitivity was predicted using the Cellminer database.
resultsWe identified a ceRNA network comprising 75 differentially expressed lncRNAs (DElncRNAs), 60 DEmiRNAs and 382 DEmRNAs, alongside a PPI network of 330 DEmRNAs. A lncRNA-miRNA-hub gene subnetwork was also constructed, involving 51 DElncRNAs, 21 DEmiRNAs, and 20 hub genes. Notably, MPP2 and FGF14-AS2, both downregulated in CRC, were associated with the prognosis. A prognostic model incorporating N stage, T stage, and FGF14-AS2 expression moderate predictive ability. Additionally, FGF14-AS2 and MPP2 showed correlations with specific chemotherapeutic agents.
conclusionsFGF14-AS2 and MPP2 are downregulated in CRC and serve as potential prognostic biomarkers. The prognostic model developed provides moderate predictive value for CRC outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.